Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:07:57.156Z.
Calculation as of: 2026-10-06T20:07:57.156Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2100d4567e155cb65401b1d64ef1112e8effddeb5d941ccec26242c7dbad22d6
PE RATIO
N/A
Market Cap
$353.88M
PE Ratio
N/A
TTM Avg
197.33
3Y Avg
88.65
5Y Avg
67.24
Market Cap
$359.53M
PE Ratio
N/A
TTM Avg
170.63
3Y Avg
170.63
5Y Avg
170.63
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $349.70M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | 84.67 | 84.67 | 84.67 |
| Embecta Corp. (EMBC)vs › | $353.00M | 4.02 | 4.83 | 10.37 | 9.91 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 197.33 | 88.65 | 67.24 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 25.65 | 24.97 | 28.19 | 31.91 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | 0.72 | 0.72 | 0.72 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 170.63 | 170.63 | 170.63 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.84
Forward EPS (Est.)
$-1.52
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
